Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise

Diabetologia

Volumn 53, Issue 1, 2010, Pages 139-143

  Khoo, E Y H ^a,b,c   Wallis, J ^b   Tsintzas, K ^b   MacDonald, I A ^b   Mansell, P ^a,b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Exenatide; Exercise; GLP 1; Glucagon like peptide 1; Hypoglycaemia

Indexed keywords

ADRENALIN; CATECHOLAMINE; EXENDIN 4; GLUCAGON; GLUCOSE; HYDROCORTISONE; INSULIN; NORADRENALIN; PLACEBO;

ADRENALIN BLOOD LEVEL; ADULT; AEROBIC EXERCISE; ARTICLE; BODY MASS; CATECHOLAMINE BLOOD LEVEL; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYCLING; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NORADRENALIN BLOOD LEVEL; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; SINGLE DRUG DOSE;

ADULT; BICYCLING; BLOOD GLUCOSE; CATECHOLAMINES; DIABETES MELLITUS, TYPE 2; EXERCISE; GLUCAGON; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; INSULIN; LACTATES; MALE; OXYGEN CONSUMPTION; PEPTIDES; REFERENCE VALUES; VENOMS;

EID: 72449207969     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1579-1     Document Type: Article

References (10)

1. LL Nielsen AD Baron 2003 Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes Curr Opin Investig Drugs 4 401 405 1:CAS:528:DC%2BD3sXkvFKktb8%3D 12808878
2. KB Degn B Brock CB Juhl, et al. 2004 Effect of intravenous infusion of exenatidee (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia Diabetes 53 2397 2403 10.2337/diabetes.53. 9.2397 1:CAS:528:DC%2BD2cXns1ShsL4%3D 15331551 (Pubitemid 39145595)
3. CM Edwards SA Stanley R Davis, et al. 2001 Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol-Endocrinol Metab 281 E155 E161 1:CAS:528:DC%2BD3MXltVKhtrg%3D 11404233
4. DM Kendall MC Riddle J Rosenstock, et al. 2005 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 1083 1091 10.2337/diacare.28.5.1083 1:CAS:528:DC%2BD2MXksF2hu7s%3D 15855571 (Pubitemid 40616617)
5. Bird S, Davison R (1997) Guidelines for the physiological testing of athletes, 3rd edn. British Association of Sport and Exercise Sciences, Leeds, pp 59-72
6. F Calara K Taylor J Han, et al. 2005 A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4) Clin Ther 27 210 215 10.1016/j.clinthera.2005.02.008 1:CAS:528:DC%2BD2MXjtFSqurg%3D 15811484 (Pubitemid 40462014)
7. GA Borg 1982 Psychophysical bases of perceived exertion Med Sci Sports Exerc 14 377 381 1:STN:280:DyaL3s7hsVChsw%3D%3D 7154893
8. CD Forster IA Macdonald 1999 The assay of the catecholamine content of small volumes of human plasma Biomed Chromatogr 13 209 215 10.1002/(SICI)1099- 0801(199905)13:3<209::AID-BMC820>3.0.CO;2-Z 1:CAS:528:DyaK1MXjsVOktbo%3D 10375120 (Pubitemid 29248375)
9. WA Muller GR Faloona RH Unger 1971 The influence of the antecedent diet upon glucagon and insulin secretion N Engl J Med 285 1450 1454 1:STN:280:DyaE38%2FkvFGmug%3D%3D 4941591
10. MA Nauck MM Heimesaat K Behle, et al. 2002 Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers J Clin Endocrinol Metab 87 1239 1246 10.1210/jc.87.3.1239 1:CAS:528:DC%2BD38XitlWnsro%3D 11889194 (Pubitemid 36121094)